Literature DB >> 17306245

Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis.

Vassiliki Matzaraki1, Krystallenia I Alexandraki, Kyriaki Venetsanou, Christina Piperi, Pavlos Myrianthefs, Nikolaos Malamos, Theodoros Giannakakis, Stelios Karatzas, Evanthia Diamanti-Kandarakis, George Baltopoulos.   

Abstract

OBJECTIVES: Procalcitonin (PCT) and interleukin-6 (IL-6) are established markers of tissue inflammation and injury. The aim of the present study was to investigate the possible correlation of PCT and IL-6 with liver metastasis. DESIGN AND METHODS: The study consisted of fifteen healthy controls (group A), twenty-one patients with solid tumors without metastases (group B), eleven patients with liver metastasis only (group C) and eleven patients with generalized metastatic disease (group D).
RESULTS: Serum PCT levels were significantly increased in group D compared to groups A (p<0.001) and B (p=0.004), but no difference was observed in PCT levels between groups C and B or C and D. IL-6 serum levels were markedly elevated in group C compared to group A (p<0.001) or to groups B (p<0.001) and D (p=0.02). A positive correlation was observed between PCT and IL-6 serum levels (r=0.357, p=0.019).
CONCLUSIONS: PCT levels are related to disease stage in cancer patients, whereas IL-6 concentration seems to be a more specific marker of liver metastasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17306245     DOI: 10.1016/j.clinbiochem.2006.10.027

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  17 in total

1.  Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma.

Authors:  Alicia Algeciras-Schimnich; Carol M Preissner; J Paul Theobald; Mary S Finseth; Stefan K G Grebe
Journal:  J Clin Endocrinol Metab       Date:  2008-12-16       Impact factor: 5.958

2.  Procalcitonin is a Poor Predictor of Non-Infectious Fever in the Neurocritical Care Unit.

Authors:  Karin Halvorson; Sameer Shah; Corey Fehnel; Bradford Thompson; N Stevenson Potter; Mitchell Levy; Linda Wendell
Journal:  Neurocrit Care       Date:  2017-10       Impact factor: 3.210

3.  Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.

Authors:  Kristen K Ciombor; Yang Feng; Al Bowen Benson; Yingjun Su; Linda Horton; Sarah P Short; John Sae Wook Kauh; Charles Staley; Mary Mulcahy; Mark Powell; Katayoun I Amiri; Ann Richmond; Jordan Berlin
Journal:  Invest New Drugs       Date:  2014-06-04       Impact factor: 3.850

4.  Role of Procalcitonin and Interleukin-6 in Predicting Cancer, and Its Progression Independent of Infection.

Authors:  Anne-Marie Chaftari; Ray Hachem; Ruth Reitzel; Mary Jordan; Ying Jiang; Ammar Yousif; Kumait Garoge; Poonam Deshmukh; Zanaib Al Hamal; Joseph Jabbour; Alexander Hanania; Sammy Raad; Mohamed Jamal; Issam Raad
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

5.  Procalcitonin Identifies Cell Injury, Not Bacterial Infection, in Acute Liver Failure.

Authors:  Jody A Rule; Linda S Hynan; Nahid Attar; Corron Sanders; William J Korzun; William M Lee
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

Review 6.  Utility of blood procalcitonin concentration in the management of cancer patients with infections.

Authors:  Bonita Durnaś; Marzena Wątek; Tomasz Wollny; Katarzyna Niemirowicz; Michał Marzec; Robert Bucki; Stanisław Góźdź
Journal:  Onco Targets Ther       Date:  2016-01-22       Impact factor: 4.147

7.  Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients.

Authors:  Baykal Tulek; Habibe Koylu; Fikret Kanat; Ugur Arslan; Faruk Ozer
Journal:  Contemp Oncol (Pozn)       Date:  2013-03-15

8.  Interleukin-6 (IL-6) serum concentrations in dogs with hepatitis and hepatic tumours compared with those with extra-hepatic inflammation and tumours.

Authors:  Stephan Neumann; Franz-Josef Kaup; Sonja Scheulen
Journal:  Comp Clin Path       Date:  2010-11-19

9.  Diagnostic Value of Procalcitonin in ANCA-Associated Vasculitis (AAV) to Differentiate Between Disease Activity, Infection and Drug Hypersensitivity.

Authors:  K Herrmann; S Schinke; E Csernok; F Moosig; J U Holle
Journal:  Open Rheumatol J       Date:  2015-10-09

10.  Knockdown of astrocyte elevated gene-1 inhibits growth through suppression of IL-6 secretion in HepG2 human hepatoma cells.

Authors:  Huan Deng; Zhenzhen Zhou; Wei Tu; Yujia Xia; Huanjun Huang; De'an Tian
Journal:  Oncol Lett       Date:  2013-10-29       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.